Help us: Donate
Follow us on:

Covalent Bioscience

Organization Description


Covalent Biosciences, Inc. is developing Cardizyme, a catabody that destroys transthyretin amyloid (misTTR). Amyloids are misfolded proteins that aggregate in harmful clumps and do not perform their original functions, and this amyloid is implicated in heart disease, spinal disorders, and other organ damage. It is one of the principal causes of death for supercentenarians, people who have lived longer than 110 years.


Sudhir Paul, Ph.D.

Covalent Bioscience - Co-founder